Non-bleeding visible vessel treatment: perendoscopic injection therapy versus omeprazole infusion.
BACKGROUND
The non-bleeding visible vessel in a peptic ulcer is the highest risk factor for a bleeding recurrence among not actively bleeding lesions. Perendoscopic injection of sclerosing compounds is usually used as prophylaxis against rebleeding.


METHODS
Forty-two patients with visible vessels in a peptic ulcer at an emergency endoscopic procedure have been studied: 21 patients underwent prophylactic perendoscopic hemostasis, and 21 patients were infused with omeprazole intravenously.


RESULTS
Eight patients (19%), four in each group, had early rebleedings (within 48 h after the enrollment). There was no significant difference between the two types of treatment. At the endoscopic control after 48 h there were significantly more lesions with higher risk of rebleeding (Forrest IIa and IIb) in the group treated with perendoscopic hemostasis.


CONCLUSIONS
Our data suggest that omeprazole infusion is a valid alternative to injection treatment of non-bleeding visible vessels.
Grosso
C
C
Gastroenterology and Digestive Endoscopy Unit, Ca' Granda Niguarda Hospital, Milan, Italy.
Rossi
A
A
Gambitta
P
P
Bini
M
M
Zanasi
G
G
Pirone
Z
Z
Arcidiacono
R
R
D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016009:Chi-Square Distribution; D005260:Female; D005773:Gastroscopy; D016558:Hemostasis, Endoscopic; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage* / Q000627:therapeutic use; D010438:Peptic Ulcer Hemorrhage / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D013276:Stomach Ulcer / Q000150:complications*; D016896:Treatment Outcome
D000897:Anti-Ulcer Agents; D009853:Omeprazole